Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 7/20 | 0.63 |
| ▸ | CDK2 | P24941 | 7/20 | 0.63 |
| ▸ | CCNA1 | P78396 | 7/20 | 0.63 |
| ▸ | IKBKB | O14920 | 12/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | CHUK | O15111 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5346277 | 0.89 | IKBKB (0.62) | CCNA2CDK2CCNA1IKBKBCHUK | |
| SCHEMBL6679993 | 0.88 | CCNA2 (0.62) | CCNA2CDK2CCNA1IKBKBSCN9A | |
| SCHEMBL6197538 | 0.88 | IKBKB (0.52) | CCNA2CDK2CCNA1IKBKB | |
| SCHEMBL5335190 | 0.87 | CCNA2 (0.48) | CCNA2CDK2CCNA1IKBKBAURKA | |
| SCHEMBL5338107 | 0.87 | IKBKB (0.51) | CCNA2CDK2CCNA1IKBKB | |
| SCHEMBL14532972 | 0.86 | CCNA2 (0.58) | CCNA2CDK2CCNA1IKBKBAURKA | |
| SCHEMBL5334053 | 0.84 | CCNA2 (0.62) | CCNA2CDK2CCNA1IKBKBAURKA | |
| SCHEMBL5339930 | 0.83 | IKBKB (0.50) | CCNA2CDK2CCNA1IKBKBCHUK | |
| SCHEMBL5347307 | 0.83 | CCNA2 (0.63) | CCNA2CDK2CCNA1IKBKBAURKA | |
| Hydrochloric Acid SCHEMBL5340008 | 0.82 | CCNA2 (0.62) | CCNA2CDK2CCNA1IKBKBAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186743-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2007-03-06 | — | — | US | claimed |
| US-6956052-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2005-10-18 | — | — | US | claimed |
| US-20040110741-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORARTION | 2004-06-10 | — | — | US | claimed |
| US-7186743-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186743-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186743-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050256180-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | BERGMANIS ARIJA A | 2005-11-17 | — | — | US | disclosed |
| US-6956052-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2005-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110741-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | CCNA2 2589/4885CDK2 392/4885CCNA1 2090/4885 |
| US-20050256180-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | CCNA2 2589/4885CDK2 392/4885CCNA1 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.